Marvel Biosciences Corp · TSXV:MRVL
Marvel Biosciences — Investor Presentation (February 2026)
15 slides from Marvel Biosciences's investor presentation, February 2026
Slide 1: Investor Presentation 2026
We are developing transformative treatments for patients with neurological and neurodevelopmental disorders through breakthrough science built on proven research. Investor Presentation 2026 Private & Confidential
Slide 2: Disclaimer
Disclaimer Forward-Looking Information and Statements This presentation contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than s
Slide 3: Problem
Problem Autism, Rett syndrome, and Fragile X share severe, lifelong impairments — yet no approved therapies address their core neurological deficits. No approved therapies address core symptoms across ASD, Rett, or Fragile X. Current care manages symptoms, not underlying neurobiology. Patients requi
Slide 4: Solution and Biological Rationale
Solution and Biological Rationale Adenosine A2A receptor antagonism modulates baseline neuronal excitability — a shared biological driver across autism, Rett syndrome, and Fragile X. A2A Receptor Antagonism Restores Baseline AUTISM SPECTRUM DISORDER (LEVELS 2–3) Neuronal Signaling1 •Core deficits dr
Slide 5: Solution and Biological Rationale
Solution and Biological Rationale MB-204 combines benchmark-level A2A antagonism with superior oral bioavailability and durable CNS efficacy – a differentiated next-generation alternative to existing A2A antagonists (istradefylline). Proven A2A Target Engagement Superior Oral Bioavailability with Du
Slide 6: Preclinical Validation: Data Highlights
Preclinical Validation: Data Highlights MB-204 rapidly restores social interaction and reverses repetitive and stereotyped behaviors across autism-relevant and affective phenotypes. Autism (Oprm1)* Forced Swimming Test Dose-dependent rescue of core social Repetitive behaviors are normalized Rapid an
Slide 7: Preclinical Validation: Data Highlights
Preclinical Validation: Data Highlights MB-204 reverses core Rett syndrome behaviors in a preclinical model, outperforming sole FDA approved treatment for Rett Rett Syndrome (MECP-/+)* Dose-dependent rescue of core social behaviors Repetitive behaviors are normalized Long-lasting, sustained followin
Slide 8: Intellectual Property
Intellectual Property Granted Composition of Matter Core composition-of-matter patents granted and pending across major markets, with planned formulation and pediatric filings to extend exclusivity. Patent Family Jurisdictions Status Coverage Granted (China, Japan, US) Purine Compounds for Treating
Slide 9: Market Opportunity
Market Opportunity TAM Neurodevelopmental Disorders TAM Revenue $180B–$490B annually ~30-40M individuals for 3 NDD SAM Individuals with ASD Level 2-3 SAM Revenue $60B–$175B annually ~10-15M individuals SOM Assuming the initial SOM Revenue (Initial Years) $3B–$18B annually commercial reach to 5-10% 0
Slide 10: Market Comparables
Market Comparables CANADIAN NEUROSCIENCE COMPARABLES Acquired 2023 for > $80M after Phase 1 In Phase 1 > $77M USD In Phase 1b/2a > $400M USD SHORT TERM RETURNS PROFILE Satellos Bioscience $140M MC Nurexone Biologic $58M MC Autolus Therapeutics $411M MC Adicet Bio $65M MC Private & Confidential
Slide 11: Timeline and Value Milestones
Timeline and Value Milestones Today 0-6 months 6-12 months 12-18 months ✓ cGMP drug product CLINICAL – Phase 1 CLINICAL – Phase 1 CLINICAL – Phase 1 manufactured and released • First-in-human dosing in • Multiple-ascending-dose • PK and exploratory biomarker ✓ GLP toxicology studies healthy voluntee
Slide 12: Phase 1 Program Scope
Phase 1 Program Scope Phase 1 Clinical Operations • CRO-managed SAD/MAD study in healthy volunteers • Safety, tolerability, PK, and exploratory biomarkers • CNS-relevant exposure confirmation CMC & Drug Supply Phase 1 clinical program designed to deliver human • GMP drug product release and stabilit
Slide 13: Meet the Team
Meet the Team J. Roderick Matheson Mark Williams, PhD Harry Nijjar, CPA, CMA CEO & Director President, CSO & Director CFO MISSION STATEMENT: A capital markets veteran with nearly 40 years of A drug development executive with 20+ years of A seasoned financial executive with extensive experience in in
Slide 14: Investment Highlights
Investment Highlights Large Neurodevelopmental Market with Phase 1-Ready with Major Development Limited Therapeutic Options RisksofRemoved NALCN sets the resting cells, shaping how they respond to signals. NALCN sets the resting of cells, shaping how they respond to signals. Severe neurodevelopmenta
Slide 15: Investor Presentation 2026
Rod Matheson Dr. Mark Williams rod@marvelbiosciences.com mark@marvelbiosciences.com 403-770-2468 431-777-7759 Investor Presentation 2026 Private & Confidential
Marvel Biosciences — Investor Presentation (February 2026) on 6ix